AZArianna Zangrilli

Arianna Zangrilli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arianna Zangrilli has a total of 138 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Interplay of Biological Treatment and Psychological Features in Patients with Psoriasis: A Real-Life Prospective Study

    by Gaia Moretta, Samela Tonia, Alessia Provini, Gianluca Pagnanelli, Dario Graceffa, Diego Orsini, Viviana Lora, Antonio Giovanni Richetta, Annunziata Dattola, Simone Amato, et al.

    Introduction: Emotional dysregulation (ED), common among patients with psoriasis, lead to psychopathology and impair treatment adherence. Objective: This study examines the changes in prevalence of ED in patients and its effects on illness perception, mental health, and quality of life (QoL) during one year of treatment with risankizumab. Method: ED, illness perception, general health and QoL were measured at baseline, and at 4, 16, and 52 weeks post-treatment in 58 patients with psoriasis. Results: Higher ED was associated with greater psychological distress and poorer QoL. Patients with higher levels of ED reported greater psychological distress, worse QoL, and higher symptom-related distress throughout treatment as compared to those with lower ones. Although both groups improved in illness perception and clinical severity outcomes, patients with high ED consistently experienced worse subjective outcomes. Conclusion: ED is frequent in psoriasis patients and negatively affects mental health and QoL, despite clinical improvements in skin symptoms. Targeted psychological interventions may be necessary for patients who exhibit higher levels of emotional dysregulation to ensure comprehensive care and better long-term outcomes.

  • Open Access

    Psoriasis in Difficult-to-Treat Areas: A Multicentre, Real-World Retrospective Study Analyzing the Impact of Non-Invasive Imaging Techniques (Dermoscopy, Reflectance Confocal Microscopy and Optical Coherence Tomography) to Monitor the Effectiveness of Risankizumab in the Treatment of Plaque Psoriasis of the Legs

    by Annunziata Dattola, Raimondo Rossi, Giuseppe Rizzuto, Giacomo Caldarola, Eleonora De Luca, Viviana Lora, Domenico Giordano, Severino Persechino, Claudio Bonifati, Diego Orsini, et al.

    Objectives: To evaluate the impact of non-invasive imaging techniques such as dermoscopy, reflectance confocal microscopy (RCM) and optical coherence tomography (OCT) to monitor the efficacy of risankizumab on plaque psoriasis of the legs by analyzing morpho-histological changes. Materials and Methods: Multicentre, real-world retrospective study involving 37 adults with moderate-to-severe plaque psoriasis. Assessments performed during routine visits at baseline, Week 4 and Week 12 included clinical response, dermoscopy, RCM and OCT. Results: Thirty-seven patients were included (mean age 52.1 years; 54% male; mean BMI 27.0 kg/m2). Dermoscopy showed progressive vascular normalization: at Week 12, 94.29% of lesions had minimal or no vascular pattern. White and yellow scales decreased significantly. On RCM, dilated vessels, inflammatory infiltrate, and papillomatosis progressively normalized. OCT showed reduction in epidermal and stratum corneum thickness and a decline in vascular intensity at multiple depths. Baseline haemorrhagic dots predicted early complete response: 44.8% of lesions with dots achieved complete clearance at Week 4 versus 0% without. Conclusions: Risankizumab induced rapid, significant regression of psoriatic changes, normalizing vascular patterns and skin architecture and reducing epidermal thickness. Findings support its efficacy and rapid onset of action in difficult-to-treat areas and highlight the value of non-invasive imaging for monitoring.


  • Open Access

    Effectiveness and Safety of Adalimumab Biosimilars in Pediatric Psoriasis: A Multi-Center International Experience

    by Cristina Bertoli, Tiago Torres, Paolo Romita, Luca Stingeni, Katharina Hansel, Luca Mastorino, Michela Ortoncelli, Michele Panzone, Maria João Cruz, Luca Bianchi, et al.

    Background: Many adalimumab biosimilars have been approved for the same indications as their originator (Humira ®). However, data on their efficacy and safety in children with psoriasis are scarce. Objective: To assess the effectiveness and safety of adalimumab biosimilars in a group of adalimumab-naïve patients and another group of patients who switched from originator adalimumab to biosimilars. The co-primary endpoints were the PASI absolute mean, PASI 75, and PASI 90 at 16, 24 and 52 weeks. Methods: In this 52-week, multi-center, non-interventional, observational, retrospective study, patients starting biosimilars in routine practice after January 2022 were enrolled at 10 sites across Italy, Portugal, and France. Disease activity scores such as the Psoriasis Area Severity Index (PASI) and safety data were captured during 12 months following adalimumab biosimilar initiation. Results: A total of 102 pediatric patients with psoriasis receiving adalimumab biosimilar therapy either as naïve (n = 72) or switching from originator adalimumab (n = 30) were enrolled. Median absolute PASI remained low at weeks 16, 24, and 52 in both groups (naïve 5.4, 4.3, 2.8; switching 2.6; 2.0; 1.4 respectively). PASI 75 response at weeks 16, 24, and 52 was observed in 41.7, 55.0, and 77.8% of patients in the naive group and 82.8%, 86.2%, and 92.6% of patients in the switch group. PASI 90 response at weeks 16, 24, and 52 was achieved by 23.3%, 26.7%, and 46.3% of patients in the naïve group and 58.6%, 65.5%, and 55.6% of patients in the switch group. Three patients discontinued biosimilars after the switch due to loss of efficacy. No emergency room visits or hospitalizations were observed during the study period and none of the patients experienced serious adverse effects. Conclusion: Adalimumab biosimilars showed a favorable effectiveness/safety profile in childhood psoriasis. Switching from reference adalimumab to biosimilars did not impact effectiveness and safety. A likelihood of discontinuation was noted in patients who switched from Humira to biosimilars.


  • Open Access

    Risankizumab for the treatment of moderate‐to‐severe psoriasis: A multicenter, retrospective, 1 year real‐life study

    by Giacomo Caldarola, Arianna Zangrilli, Nicoletta Bernardini, Mauro Bavetta, Clara De Simone, Dario Graceffa, Claudio Bonifati, Sara Faleri, Domenico Giordano, Marco Mariani, et al.

    Several new biologic agents targeting IL23/Th17 axis, such as risankizumab, have been developed for the treatment of psoriasis. The aim of the present study was to analyze the efficacy and safety of risankizumab in patients with moderate‐to‐severe psoriasis over a 52‐week period. A multicentric retrospective study was conducted in patients who initiated risankizumab between July 2019 and December 2020. Psoriasis Area and Severity Index—PASI was measured at baseline and after 4, 16, 28 and 52 weeks. Clinical responses were evaluated by PASI75, PASI90 and PASI100 at the same timepoints. Potential safety issues and adverse events (AEs) were collected. Univariable and multivariable logistic regressions were performed for variables predicting clinical response. One hundred and twelve patients with psoriasis were included. PASI90 response was achieved by 17.86% of patients at week 4, 72.22% at week 16, 91.0% at week 28 and 95.24% at week 52 (as observed analysis). No associations between the considered variables and the efficacy endpoints were retrieved, influence of variables such as Body Mass Index (BMI), baseline PASI or previous biologics were not shown. No serious safety issues or discontinuations related to adverse events were reported. Risankizumab showed high efficacy and a favorable safety profile, regardless of patient‐ and disease‐related factors.


  • Open Access

    Prevalence of Atherosclerosis in Psoriatic Patients Detected with Epiaortic Color Doppler Ultrasound and Computed Tomography Angiography

    by Annunziata Dattola, Guglielmo Manenti, Donatella Ferrari, Laura Vollono, Salvatore Marsico, Feliciana Lamacchia, Maria Esposito, Mattia Marchesano, Arianna Zangrilli, Roberto Floris, et al.

    Introduction: Psoriasis (PsO), a chronic inflammatory, multisystemic, and multifactorial disease can cause endothelial dysfunction, artery calcification, and atherosclerotic disease. A higher incidence of vascular occlusive events has been observed in psoriatic patients compared to healthy controls, and multiple studies confirm the association between moderate-severe PsO and atherosclerosis, coronary artery calcification, and higher cardiovascular risk. Objective: We sought to analyze atherosclerotic disease prevalence in epiaortic vessels of psoriatic and non-psoriatic patients to understand if PsO could represent an independent risk factor predisposing to atherosclerotic disease. Methods: We evaluated 47 psoriatic patients without cardiovascular risk factors with color Doppler ultrasound (CDUS). If atheromatous plaques were detected, a computed tomography angiography (CTA) was performed. We evaluated 47 non-psoriatic patients without cardiovascular risk factors with CDUS. Atherosclerosis prevalence in both groups were statistically analyzed. CDUS performance was compared to CTA. Results: In the psoriatic group (mean age 50.9 years), 6 had atheromatous plaques and 12 had an intima-media thickness (IMT) > 1 mm (overall prevalence of atherosclerotic disease: 38.2%). All plaques detected with CDUS were confirmed at CTA. In the control group (mean age 51.3 years), CDUS revealed atheromatous plaques in 4 patients and IMT > 1 mm in 4 ones (overall prevalence of 17%). The difference of atherosclerotic disease prevalence between the groups was statistically significant (P < 0.05). Conclusion: Our results highlight that PsO could be considered a predisposing factor for atherosclerotic disease development in epiaortic vessels, as it causes an increased IMT, that is also considered an independent cardiovascular risk factor.


  • Open Access

    Risankizumab for Plaque and Guttate Psoriasis in a Patient With IgA-Related Glomerulonephritis

    by Annunziata Dattola, Arianna Zangrilli, Luca Bianchi

    Citation: Dattola A, Zangrilli A, Bianchi L. Risankizumab for plaque and guttate psoriasis in a patient with IgA -related glomerulonephritis. Dermatol Pract Concept. 2021;11(4):e2021100. DOI: https://doi.org/10.5826/dpc.1104a100 Accepted: March 8, 2021; Published: October, 2021 Copyright: ©2021 Dattola et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License BY-NC-4.0, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited. Funding: None. Competing interests: None. Authorship: All authors have contributed significantly to this publication. Corresponding author: Annunziata Dattola, Department of Dermatology, Policlinico Tor Vergata, Rome, Italy. Email: nancydattola@gmail.com Keywords : guttate psoriasis, plaque psoriasis, risankizumab, renal disease This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


  • Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy

    by Arianna Zangrilli, Giacomo Caldarola, Nicoletta Bernardini, Mauro Bavetta, Dario Graceffa, Claudio Bonifati, Franca Cantoresi, Sara Faleri, Domenico Giordano, Marco Mariani, et al.

    Efficacy of anti-TNF-a agents seems inferior to IL-17 and IL-23 inhibitors. Nevertheless, after biosimilars approval, anti TNF-a agents are recommended as first-line for psoriatic patients, for eco...


  • A linear forehead lesion caused by intralesional injection of triamcinolone acetonide and treated with hyaluronic acid filler: Case report

    by Arianna Piccolo, Chiara Pensa, Arianna Zangrilli, Mauro Bavetta, Laura Diluvio, Luca Bianchi

    Intralesional steroid injection is a treatment method frequently used to resolve a large number of orthopedic, rheumatological, dermatological, and neurological disorders. Although this treatment is very effective, it is not without possible side effects, both systemic and local, among which we can mention pain, bleeding, ulceration, atrophy, pigmentary changes, calcification, secondary infections, formation of granulomas, allergic reactions and, in very rare cases, the development of linear atrophy, and hypopigmentation. Here, we present a case of frontal linear skin atrophy after intralesional steroid injection for the treatment of alopecia areata (AA) in a 29 year‐old patient, successfully treated with a hyaluronic acid filler.


  • Risankizumab: How to choose the right dose in clinical practice?

    by Chiara Pensa, Arianna Piccolo, Arianna Zangrilli, Mauro Bavetta, Luca Bianchi

    Click on the article title to read more.

  • Ixekizumab: One drug for an enigmatic psoriasis

    by Arianna Piccolo, Chiara Pensa, Arianna Zangrilli, Mauro Bavetta, Augusto Orlandi, Luca Bianchi

    Click on the article title to read more.